Vivimed Labs Ltd (VIVIMEDLAB) is currently trading at 6.11 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vivimed Labs Limited is an integrated specialty chemicals and pharmaceutical manufacturer focused on personal care actives, APIs and finished-dose formulations, operating cGMP chemical plants in Bidar and Bonthapalli and multiple formulations facilities in Jeedimetla, Kashipur and Haridwar with subsidiaries in the USA, UK, Hong Kong and Mauritius to serve global customers and contract manufacturing clients. The company reported severe financial stress in FY26 with consolidated audited net losses exceeding Rs.1.7 billion, consolidated negative equity of about Rs.2.1 billion, total consolidated assets of Rs.7.53 billion against liabilities of Rs.9.64 billion, and material audit qualifications including an unrecorded interest exposure of approximately Rs.625.7 million. A material corporate development is the initiation of CIRP by NCLT (admission dated 15 April 2026), appointment of an Interim Resolution Professional, the first CoC meeting in May 2026 and active restructuring steps including assignment of SBI debt to an ARC and negotiated one-time settlement discussions with multiple lenders. The FY26 audit raised multiple red flags: inventory write-downs of roughly Rs.233.08 million due to unusable WIP and returned goods, unsecured advances of about Rs.372.69 million with recoverability uncertainty, inability to obtain external confirmations for key borrowings, and ongoing CBI investigation related to legacy lender complaints, all creating material uncertainty about continuity and asset recoverability.

Over the past 52 weeks, Vivimed Labs Ltd has traded between a low of ₹4.76 and a high of ₹27.99. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vivimed Labs Ltd has a market capitalization of approximately 50.66. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vivimed Labs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -0.29 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 50.66 Cr, Vivimed Labs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vivimed Labs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vivimed Labs Ltd is -0.29. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vivimed Labs sought a three-month extension from the Registrar of Companies, Bangalore (Karnataka) to convene its FY26 Annual General Meeting.

Vivimed Labs informed BSE that a Committee of Creditors meeting is scheduled for September 10, 2026.

Vivimed Labs intimated BSE that its 6th Committee of Creditors (CoC) meeting under the Corporate Insolvency Resolution Process will be held on August 18, 2026.